Effects of pioglitazone on the components of diabetic dyslipidaemia: Results of double-blind, multicenter, randomised studies

International Journal of Clinical Practice

Volumn 58, Issue 10, 2004, Pages 907-912

  Khan, Mehmood ^a,c   Xu, Y ^a   Edwards, G ^b   Urquhart, R ^b   Mariz, S ^b  

^a TAKEDA PHARMACEUTICALS   (United States)

^b Takeda Global Research and Development Centre (Europe) Ltd   (United Kingdom)

^c NONE   (United States)

Author keywords

Cardiovascular disease; Cholesterol; Insulin resistance; Lipids; Piolitazone; Type 2 diabetes

Indexed keywords

CHOLESTEROL; FATTY ACID; GLICLAZIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; METFORMIN; PIOGLITAZONE; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TREATMENT OUTCOME;

ADULT; AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FATTY ACIDS, NONESTERIFIED; FEMALE; GLICLAZIDE; HUMANS; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; METFORMIN; MIDDLE AGED; PROSPECTIVE STUDIES; THIAZOLIDINEDIONES; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 10444243290     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2004.00258.x     Document Type: Article

References (25)

1. Despres JP, Lamarche B, Mauriege P et al. Risk factors for ischaemic heart disease: is it time to measure insulin? Eur Heart J 1996; 17: 1453-4.
2. Howard G, O'Leary DH, Zaccaro D et al. Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation 1996; 93: 1809-17.
3. Garg A, Grundy SM. Management of dyslipidemia in NIDDM. Diabetes Care 1990; 13: 155-69.
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285: 2486-97.
5. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 2003; 26 (Suppl 1): S83-S86.
6. Sacks FM, Tonkin AM, Craven T et al. Coronary heart disease in patients with low LDL cholesterol. Benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation 2002; 105: 1424-8.
7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 2003; 361: 2005-16.
8. George PB, Tobin KJ, Corpus RA et al. Treatment of cardiac risk factors in diabetic patients: How well do we follow the guidelines? Am Heart J 2001; 142: 857-63.
9. Pearson TA, Laurora I, Chu H et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459-67.
10. Inzucchi S, Chyun D, Young L et al. What defines 'excellent' diabetes control? An analysis of cardiovascular disease risk factors in patients with type 2 diabetes at target HbA1c. In: Program and Abstracts of the 63rd Scientific Sessions of the American Diabetes Association. New Orleans: June 13-17 2003, A157. [Abstract 674-P].
11. Massing MW, Foley KA, Sueta CA et al. Trends in lipid management among patients with coronary artery disease: Has diabetes received the attention it deserves? Diabetes Care 2003; 26: 991-7.
12. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes. JAMA 2002; 287: 360-72.
13. Aronoff S, Rosenblatt S, Braithwaite S et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes mellitus: a six-month, randomized, placebo-controlled dose-response study. Diabetes Care 2000; 23 1605-11.
14. Einhorn D, Rendell M, Rosenzweig J et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther 2000; 22: 1395-409.
15. Kipnes MS, Krosnick A, Rendell MS et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001; 111: 10-17.
16. Khan M, Perez A, Johnson T et al. Pioglitazone in combination with insulin results in changes in lipid subspecies and subparticle profiles in patients with type 2 diabetes. In: Program and Abstracts of the 18th Congress of the International Diabetes Federation. Paris: August 24-29 2003, 74. [Abstract 204].
17. King AB, Armstrong DU. Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review. Diabetes Technol Ther 2002; 4: 145-51.
18. Hanefeld M, Brunetti P, Schernthaner GH et al. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004; 27: 141-7.
19. Takeda Europe Research and Development Centre Ltd., Data on file, study 404.
20. Takeda Europe Research and Development Centre Ltd., Data on file, study 405.
21. Matthews DR, Charbonnel BH, Hanefield M et al. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients for type 2 diabetes: a randomised, comparative study. Diabetes Metab Res Rev 2004 (in press).
22. Rubins HB, Robins SJ, Collins D et al. Diabetes, plasma insulin, and cardiovascular disease. Arch Intern Med 2002; 162 2597-604.
23. Glazer B, Perez A, Johnson T et al. Pioglitazone in combination with metformin results in changes in lipid subspecies and subparticle profiles in patients with type 2 diabetes. In: Program and Abstracts of the 18th Congress of the International Diabetes Federation. Paris: August 24-29 2003, 45319. [Abstract 2564].
24. Murray FT, Perez A, Johnson T et al. Pioglitazone in combination with sulfonylurea results in changes in lipid subspecies and subparticle profiles in patients with type 2 diabetes. In: Program and Abstracts of the 18th Congress of the International Diabetes Federation. Paris: August 24-29 2003, 354. [Abstract 1029].
25. Lamarche B, Tchernof A, Moorjani S et al. Small, dense, low-density lipoprotein particles as predictor of the risk of ischemic disease in men: prospective results from the Quebec Cardiovascular Study. Circulation 1997; 94: 69-75.